Emgality is the only calcitonin gene-related peptide (CGRP) antibody FDA approved with specific doses for both migraine and episodic cluster headache1,2

For the preventive treatment of migraine in adults1

Migraine recommended dosing1a:

Dosing of Emgality pen for first month and subsequent months

aThe Emgality Pen and prefilled syringe needles are 27 gauge x 1/2 inch.3

Migraine Rx facts1:

Method of administration:
Pen or prefilled syringe

Monthly dosing strength:
120 mg

Loading dose:

  • Month 1: 240 mg (2 consecutive subcutaneous [SC] injections of 120 mg each) once as a loading dose
  • 2 packages with the same NDC must be dispensed when a loading dose is prescribed

Subsequent monthly dose:

  • Subsequent months: 120 mg SC injection once per month

For the the treatment of episodic cluster headache in adults1

Cluster recommended dosing during an active cluster period1b:

Dosing of Emgality for one 300 mg dose is three syringe injections of 100 mg

bThe Emgality prefilled syringe is 27 gauge x 1/2 inch.4

Cluster headache Rx facts1:

Method of administration:
Prefilled syringe

Monthly dosing strength:
300 mg

Recommended dosing1:

  • 300 mg administered as 3 consecutive SC injections of 100 mg each, at the onset of the cluster period, and then monthly until the end of the cluster period
    • 300 mg dose; this comes in 3 x 100 mg prefilled syringes
    • These 3 syringes are administered subcutaneously, one after another
  • Patients begin treatment at the onset of a cluster period
  • Patients take this 300 mg dose every month until their cluster period ends

SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Safety across 4 studies
Review safety profile of 120 mg and 300 mg doses



How to locate and prescribe Emgality using the Electronic Media Record (EMR) system

Magnifying glass icon

Search for “Emgality”

EMR screen icon

In the EMR system, select the formulation for your patient’s diagnosis1:



Emgality Pen 120 mg/mL SC injection | NDC 0002-1436-11 | Qty: 1 per box


Emgality Syringe 120 mg/mL SC injection | NDC 0002-2377-11 | Qty: 1 per box


Emgality Syringe 100 mg/mL SC injection | NDC 0002-3115-09 | Qty: 3 per box


Prescription icon

Prescribe the appropriate dose for your patient:


Emgality 120 mg for migraine

Loading Dose
(Use only if the patient does not begin treatment with a Loading Dose Kit [sample]C in the office)
Dispense: 2 pens or syringes at once with 0 refills
Maintenance Dose
(Use for all patients with migraine)
Dispense: 1 pen or syringe once monthly with 10 refills

cLoading Dose Kits (samples) are intended to establish tolerability and efficacy for a patient.


Emgality 300 mg for episodic cluster headache

Recommended Dose
Sig: 3 SC injections once monthly during an active cluster period
Dispense: (3) 100 mg prefilled syringes with 3 refills

SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Discover how eligible patients can get Emgality for as little as $0 for up to 12 monthsd

dTerms and Conditions: Offer good until 12/31/2021 for up to 12 months of Emgality. Patients with commercial drug insurance may be able to pay as little as $0 for their first fill of Emgality. For the 2nd and subsequent fills, patients must have coverage for Emgality through their commercial drug insurance plan to continue to pay as little as $0 per fill. Offer subject to a monthly savings of wholesale acquisition cost plus usual and customary pharmacy charges and a separate $4900 maximum annual savings. Participation in the program requires a valid patient HIPAA authorization. Patient is responsible for any applicable taxes, fees, or amounts exceeding monthly or annual caps. This offer is invalid for patients without commercial drug insurance or those whose prescription claims are eligible to be reimbursed, in whole or in part, by any governmental program, including, without limitation, Medicaid, Medicare, Medicare Part D, Medigap, DoD, VA, TRICARE®/CHAMPUS, or any state patient or pharmaceutical assistance program. Offer void where prohibited by law and subject to change or discontinue without notice. Card activation is required. Subject to additional terms and conditions, which can be found here.


References: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC. 2. Data on File. Lilly USA, LLC. DOF-GZ-US-0085. 3. Data on File. Lilly USA, LLC. DOF-GZ-US-0060. 4. Data on File. Lilly USA, LLC. DOF-GZ-US-0071.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 10DEC2019